Browse EX-10 agreements

GREENWAY TECHNOLOGIES, INC.

STOCK AWARD AGREEMENT

1. Grant of Award. Pursuant to the terms of this Stock Award Agreement (this “Agreement”) and in exchange for services rendered to Greenway Technologies, Inc., a Texas corporation (the “Company”), the Company hereby grants to Doug Cogan (the “Grantee”) an award of 2,500,000 shares (the “Awarded Shares”) of the Company’s common stock, $0.001 par value (“Common Stock”). The “Date of Grant” of this Award is June 12, 2026.

2. Definitions. For purposes of this Agreement, the following terms shall have the meanings set forth below:

 

(a) “Employment Agreement” means that certain Employment Agreement, dated June 12, 2026, by and between the Company and the Grantee.

…

2

 

3

 

4

 

5

 

6

 

7

 

8

 

9

 

10

 

11

 

12

 

13

 

14

 

15

 

16

 

17

2

 

3

Exhibit 10.1

 

SECURITIES PURCHASE AGREEMENT

This Securities Purchase Agreement (this “Agreement”) is dated as of June 11, 2026 between Arcadia Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an exemption from registration requirements of Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

ARTICLE I.

DEFINITIONS

…

Exhibit 10.2

 

REGISTRATION RIGHTS AGREEMENT

 

This Registration Rights Agreement (this “Agreement”) is made and entered into as of June 11, 2026, between Arcadia Biosciences, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).

 

This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser (the “Purchase Agreement”).

 

The Company and each Purchaser hereby agrees as follows:

 

1. Definitions.

 

Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings:

 

“Advice” shall have the meaning set forth in Section 6(c).

…

Execution Copy

AMENDMENT NO. 7 TO AMENDED AND RESTATED CREDIT****AGREEMENT

This AMENDMENT NO. 7 TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Agreement”) is made as of June 9, 2026, by and among SAFETY INSURANCE GROUP, INC., a Delaware corporation (the “Borrower”), the lenders who are or may become party to the Credit Agreement referred to below (collectively, the “Lenders”), and CITIZENS BANK, N.A., as administrative agent for the Lenders (the “Administrative Agent”).  Capitalized terms used and not defined in this Agreement shall have the meanings ascribed thereto in the Credit Agreement referred to below.

WHEREAS, the Borrower, the Lenders, and the Administrative Agent are parties to that certain Amended and Restated Revolving Credit Agreement, dated as of August 14, 2008, among the Borrower, the Administrative Agent and the Lenders (as amended, restated or otherwise modified from time to time, the “Credit Agreement”);

…

Document

EXHIBIT 10.1

TRANSITION AND RELEASE AGREEMENT

THIS TRANSITION AND RELEASE AGREEMENT (“Agreement”) is made by and between Christopher J. Reedy (“Employee”) and Butler National Corporation, a Kansas corporation (the “Company”).

WHEREAS, Employee has provided notice to the Board of Directors of the Company (the “Board”) of his decision to retire as the Chief Executive Officer of the Company on June 15, 2026 (the “Resignation Date”);

WHEREAS, Employee has informed the Company of his intent to take a leave of absence from the Company commencing on or prior to the Resignation Date;

WHEREAS, for periods on and after the Resignation Date and continuing until the end of the day on July 1, 2027 (the “Retirement Date”), the Board desires that Employee remain employed by the Company as a Special Advisor to the Board;

WHEREAS, the Company and Employee desire to enter into this Agreement with respect to their respective rights and obligations in connection with Employee’s retirement and employment as a Special Advisor to the Board; and

…

AMENDED AND RESTATED EMPLOYMENT AGREEMENT FOR HUSSEIN SWEITI

THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is entered into by and between enGene USA, Inc., its successors and assigns (the “Company”) and Hussein Sweiti (the “Executive”) as of the date first written below.

WHEREAS, the Company and the Executive previously entered into an Employment Agreement dated as of September 29, 2025 (“September 29, 2025 Agreement”); and

WHEREAS, the Company has determined that it is in the best interest of the Company to continue the services and employment of the Executive as its Chief Medical Officer and the Executive desires to serve in such capacity on behalf of the Company.

NOW, THEREFORE, in consideration of the premises and of the mutual covenants and agreements hereinafter set forth, the Company and the Executive hereby agree as follows:

Employment.

(a)

…

SECOND AMENDED & RESTATED EMPLOYMENT AGREEMENT

FOR ANTHONY CHEUNG

 

THIS SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of February 27, 2026, by and between enGene Inc. (the “Company”) and Anthony Cheung (the “Executive”).

 

WHEREAS, the Company and the Executive previously entered into an Employment Agreement dated November 8, 2023 (“November 8, 2023 Agreement”);

 

WHEREAS, the Company and the Executive previously entered into an Amended & Restated Employment Agreement dated October 16, 2024 (“October 16, 2024 Agreement”);

 

WHEREAS, the Company has determined that it is in the best interest of the Company to continue the services and employment of the Executive as its Chief Scientific Officer, and the Executive is willing to render such services on the terms and conditions set forth herein; and

 

WHEREAS, the parties desire to amend and restate the October 16, 2024 Agreement to reflect such terms and conditions as set forth herein this Agreement.

…

EMPLOYMENT AGREEMENT

This Employment Agreement (the “Agreement”) is effective as of the 15th day of June, 2026 (the “Effective Date”) by and between SAFESPACE GLOBAL CORPORATION, a Nevada corporation (“SSGC”), and Michael L. Hrynuik (“Executive”).

 

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and conditions contained herein, the parties hereto agree as follows:

 

1. Employment. SSGC hereby employs Michael L. Hrynuik, to serve SSGC as an Executive Officer and, specifically as its Chief Financial Officer (“CFO”), with such specific duties and responsibilities as may be required of such a CFO and as otherwise determined by the Chairman and Chief Executive Officer (“CEO”) and/or Board of Directors of SSGC (“BOD”) from time to time. Mr. Hrynuik (“Executive”) hereby accepts such Employment upon the terms and subject to conditions set forth in this Agreement. In performing his services to SSGC, the Executive will directly report and be subject to the direction of the CEO, The Employment of the Executive

…

Ohmyhome Limited

243 Alexandra Road

#02-01 BS Centre

Singapore 159932

 

12 June 2026

 

Re: Director Offer Letter

Dear WONG TAI KOK:

 

Ohmyhome Limited, a Cayman Islands limited liability company (the “Company” or “we”), is pleased to offer you a position as an Independent Director of the Company. We believe your background and experience will be a significant asset to the Company and we look forward to your participation as an Independent Director in the Company. Should you choose to accept this position as an Independent Director, this letter agreement (the “Agreement”) shall constitute an agreement between you and the Company and contains all the terms and conditions relating to the services you agree to provide to the Company. Your appointment shall begin on 12 June 2026.

…